Search clinical trials for: Bruton tyrosine kinase (BTK)

Total 8909 results

Biogen

Completed

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

Systemic Lupos Erythematosus, SLE

United States
Acerta Pharma BV

Active, not recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Chronic Lymphocytic Leukemia

Austria, Italy, Spain, United Kingdom, Belgium, Taiwan, France, Korea, Republic of, Hungary, United States, Ukraine, Canada, Australia, Germany, Israel, Czechia, Russian Federation, Slovakia, Poland, Bulgaria, New Zealand, Sweden, C... and more
National Institute of Neurological Disorders and...

Active, not recruiting

Tolebrutinib, a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

Multiple Sclerosis

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Ascentage Pharma Group Inc.

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

CLL/SLL

Russian Federation
Celgene
The Leukemia and Lymphoma Society

Completed

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | B Cell Non-Hodgkin's Lymphoma

United States
BeiGene

Recruiting

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

B-cell Malignancies

China, Italy, United States, Spain, United Kingdom, Poland, Czechia, Netherlands, Greece, France, Sweden, Korea, Republic of, Turkey
Sunnybrook Health Sciences Centre
AstraZeneca

Recruiting

Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (BRAWM)

Waldenstrom Macroglobulinemia

Canada
Abbott Medical Devices

Active, not recruiting

LIFE-BTK Randomized Controlled Trial (LIFE-BTK)

Critical Limb Ischemia (CLI)

United States, Hong Kong, Australia, New Zealand, Singapore, Taiwan
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Germany
Abbott Medical Devices

Active, not recruiting

LIFE-BTK PK Sub-study

Critical Limb Ischemia (CLI)

Taiwan, United States, Australia
The Lymphoma Academic Research Organisation
Janssen Pharmaceutica N.V., Belgium

Terminated

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (BIBLOS)

B-cell Lymphoma

France, Belgium
Peking University People's Hospital
Qilu Hospital of Shandong University; Beijing Tongren Hospital; Beijing Hospital and other collaborators

Not yet recruiting

The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Immune Thrombocytopenia
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)

Lymphoma, Mantle-Cell

United States, China, Spain, Belgium, Canada, Australia, Czechia, Italy, Taiwan, Germany, Japan, New Zealand, United Kingdom, Denmark, Brazil, Israel, France, Netherlands, Korea, Republic of, Poland, Hungary, Austria, Switzerland, Por... and more
Institute of Hematology & Blood Diseases Hospital...

Recruiting

The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Refractory/Relapsed Autoimmune Hemolytic Anemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers

Healthy Adult Subjects

China
Dr. Sabrina Overhagen

Active, not recruiting

MOTIV Bioresorbable Scaffold in BTK Artery Disease (MOTIV BVS BTK)

Peripheral Arterial Disease | Critical Limb Ischemia

Austria, Germany
Medtronic Endovascular

Completed

Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia (INPACT-DEEP)

Critical Lower Limb Ischemia

Germany, Belgium, Netherlands, Switzerland, Austria, Italy
Principia Biopharma, a Sanofi Company
Principia Biopharma Australia Pty Ltd.

Completed

A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris

Pemphigus Vulgaris

Israel, Australia, Greece, Croatia, France
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK

Hepatic Impairment

Germany
Assistance Publique - Hôpitaux de Paris
Boston Scientific Corporation

Unknown

An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK) (RANGER-BTK)

Peripheral Vascular Diseases | Lower Limb Ischemia

France
Memorial Sloan Kettering Cancer Center
Pharmacyclics LLC.; Janssen Biotech, Inc.

Recruiting

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

United States
Shanghai Children's Medical Center

Unknown

Mutation of the BTK Gene and Genotype-phenotype Correlation of Chinese Patients With X-Linked Agammaglobulinemia

Agammaglobulinemia, BTK

China
Spectranetics Corporation

Completed

ILLUMENATE Below-The-Knee (BTK) Arteries: a Post Market Clinical Study (BTK PMS)

Peripheral Arterial Disease

Netherlands, Germany, United Kingdom
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Primary Central Nervous System Lymphoma (PCNSL) | Marginal Zone Lymphoma (MZL) | Waldenstrom Macroglobulinemia (WM) | Diffuse Large B Cell Lymphoma (DLBCL)

United States, United Kingdom, Netherlands
Xuanwu Hospital, Beijing

Recruiting

An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

Neuromyelitis Optica

China
Principia Biopharma, a Sanofi Company
Massachusetts General Hospital

Active, not recruiting

Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Patients

Immunoglobulin G4 Related Disease

United States, Canada, France, Italy, Spain
BeiGene

Recruiting

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Cagent Vascular LLC

Completed

The PRELUDE BTK Study

Peripheral Arterial Disease | Critical Limb Ischemia

New Zealand, Austria, Germany, Poland
Vascuros Medical Pte Ltd
Novella Clinical

Unknown

The VaSecure BTK Study

Peripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease

Singapore, Belgium, Germany
Flanders Medical Research Program

Completed

PREVENT: Promus BTK (PREVENT)

Peripheral Arterial Disease

Belgium, Germany, New Zealand
Sengkang General Hospital

Recruiting

Promus PREMIER Below The Knee Registry

Peripheral Arterial Disease | Arterial Disease | Arterial Disease of Legs

Singapore
Nanfang Hospital of Southern Medical University

Enrolling by invitation

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Acute Myeloid Leukemia | FLT3-ITD Mutation | Brutons Tyrosine Kinase

China
Novartis Pharmaceuticals

Terminated

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Chronic Lymphocytic Leukemia (CLL)

United States
Peking University People's Hospital
Qilu Hospital of Shandong University; Beijing Tongren Hospital; Beijing Hospital and other collaborators

Not yet recruiting

Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia

Immune Thrombocytopenia

China
Nurix Therapeutics, Inc.

Active, not recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Primary Central Nervous System Lymphoma (PCNSL) | Marginal Zone Lymphoma (MZL) | Waldenstrom Macroglobulinemia (WM)

United States
Acerta Pharma BV

Withdrawn

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma
REVA Medical, Inc.

Recruiting

MOTIV BTK Randomized Controlled Trial

Critical Limb Ischemia

United States, Germany
Concept Medical Inc.

Recruiting

ABLUMINUS DES BTK Registry - FIM

Atherosclerosis | Peripheral Artery Disease | Arterial Disease of Legs

Singapore
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Waldenström Macroglobulinemia (WM)

Spain, United States, United Kingdom, France, Italy, Greece, Netherlands
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Mantle Cell Lymphoma (MCL)

United States, Poland, Italy
National Cancer Institute (NCI)

Recruiting

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | NHL | DLBCL

United States
Peking University People's Hospital

Recruiting

Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

B-cell Lymphoma

China
Concept Medical Inc.

Completed

Clinical Use and Safety of the Xtreme Touch (Magic Touch PTA)- Neo Sirolimus Coated PTA Balloon Catheter in the Treatment of Infrainguinal Peripheral Arterial Disease (XTOSI)

Atherosclerosis | Peripheral Artery Disease

Singapore
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor ((CITADEL-205))

Lymphoma

United States, Spain, France, United Kingdom, Czechia, Israel, Belgium, Italy, Germany, Poland, Denmark
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells

B-cell Non Hodgkin Lymphoma

China
Jason Robert Gotlib
National Cancer Institute (NCI)

Terminated

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Systemic Mastocytosis | Mast Cell Leukemia | Aggressive Systemic Mastocytosis

United States
Celgene

Completed

Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...

United States
Sanofi

Active, not recruiting

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Secondary Progressive Multiple Sclerosis

United States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more

Search clinical trials for: Bruton tyrosine kinase (BTK)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations